Standards for the care of people with cystic fibrosis; establishing and maintaining health
Language English Country Netherlands Media print-electronic
Document type Review, Journal Article
Grant support
MR/T041285/1
Medical Research Council - United Kingdom
PubMed
38129255
DOI
10.1016/j.jcf.2023.12.002
PII: S1569-1993(23)01727-7
Knihovny.cz E-resources
- Keywords
- Cystic fibrosis, ECFS, Guidance, Health, Standards,
- MeSH
- Cystic Fibrosis * drug therapy MeSH
- Respiratory System Agents * therapeutic use MeSH
- Humans MeSH
- Mutation MeSH
- Cystic Fibrosis Transmembrane Conductance Regulator genetics MeSH
- Electronic Nicotine Delivery Systems * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Respiratory System Agents * MeSH
- Cystic Fibrosis Transmembrane Conductance Regulator MeSH
This is the second in a series of four papers updating the European Cystic Fibrosis Society (ECFS) standards for the care of people with CF. This paper focuses on establishing and maintaining health. The guidance is produced using an evidence-based framework and with wide stakeholder engagement, including people from the CF community. Authors provided a narrative description of their topic and statements, which were more directive. These statements were reviewed by a Delphi exercise, achieving good levels of agreement from a wide group for all statements. This guidance reinforces the importance of a multi-disciplinary CF team, but also describes developing models of care including virtual consultations. The framework for health is reinforced, including the need for a physically active lifestyle and the strict avoidance of all recreational inhalations, including e-cigarettes. Progress with cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy is reviewed, including emerging adverse events and advice for dose reduction and interruption. This paper contains guidance that is pertinent to all people with CF regardless of age and eligibility for and access to modulator therapy.
Assistance Publique Hôpitaux de Paris Université Paris Cité Paris France
Copenhagen CF center Rigshospitalet Copenhagen Denmark
Cork Centre for Cystic Fibrosis Cork University Hospital Cork Ireland
Cystic Fibrosis Europe Brussels Belgium and the Belgian CF Association Brussels Belgium
Department of Nutrition and Dietetics Royal Alexandra Children's Hospital Brighton UK
Department of Paediatric Respiratory and Sleep Medicine Royal Hospital for Children Glasgow UK
Department of Psychiatry Massachusetts General Hospital Harvard Medical School Boston USA
Department of Respiratory Medicine The Children's Hospital at Westmead Sydney NSW Australia
Department of Women's and Children's Health University of Liverpool Liverpool UK
Divison of Pediatric Respiratroy Medicine BC Childrens Hospital Vancouver Canada
Epidemiology Biostatistics and Prevention Institute University of Zurich Zurich Switzerland
Haga Teaching Hospital Pharmacy The Hague Netherlands
Hospital Necker Enfants Malades AP HP CF centre Université Paris Descartes Paris France
Hospital Universitari Vall d'Hebron Barcelona Spain
IRCCS Istituto Giannina Gaslini Via Gerolamo Gaslini 5 16147 Genova Italy
Medical Center University of Freiburg Pharmacy Hugstetter St 55 Freiburg D 79106 Germany
National Resource Centre for Cystic Fibrosis Oslo University Hospital Oslo Norway
Sydney Children's Hospital Australia
The Graub CF Center Pulmonary Institute Schneider Children's Medical Center Petah Tikva Israel
University Hospital Southampton NHS Foundation Trust Southampton United Kingdom
University of Leuven Leuven Belgium
West Midlands Adult CF Centre Heartlands Hospital Birmingham UK
West of Scotland Adult CF Centre Queen Elizabeth University Hospital Glasgow UK
References provided by Crossref.org